Refining a Claims‐based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 1875-9114|38|2|172-180

ISSN： 0277-0008

Source： PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol.38, Iss.2, 2018-02, pp. : 172-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis

By Bonafede Machaon   Joseph George J.   Princic Nicole   Harrison David J.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1120-1128

Informa Healthcare

Access to resources Recommend Favorite

Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 7, 2015-07 ,pp. : 947-955

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 6, 2015-06 ,pp. : 1456-1464

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab

By Kalyoncu Umut   Karadag Omer   Akdogan Ali   Kisacik Bunyamin   Erman Mustafa   Erguven Sibel   Ertenli A. Ihsan  

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 5, 2007-01 ,pp. : 475-478

Informa Healthcare

Access to resources Recommend Favorite

Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab

By  

Current Drug Safety, Vol. 9, Iss. 1, 2014-03 ,pp. : 69-72

Bentham Science Publishers

Access to resources Recommend Favorite